N-(4-氨基苯基)噻吩-2-甲酰胺 | 39880-86-9

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: N-(4-氨基苯基)噻吩-2-甲酰胺
• 英文名称: N-(4-aminophenyl)thiophene-2-carboxamide
• CAS: 39880-86-9
• 化学式: C₁₁H₁₀N₂OS
• mdl: MFCD02258055
• 分子量: 218.279
• InChiKey: JAANUULEQHTUGY-UHFFFAOYSA-N

物化性质

• 溶解度：
  >32.7 [ug/mL]

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  15
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83.4
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险等级：
  IRRITANT

反应信息

• 作为反应物：
  描述：

  N-(4-氨基苯基)噻吩-2-甲酰胺 在 一水合肼 作用下， 以 四氢呋喃 、 乙醇 为溶剂， 反应 4.5h， 生成 N-(4-(4-Hydrazinyl-4-oxobutanamido)phenyl)thiophene-2-carboxamide (24)
  参考文献：
  名称：

  Design and Biological Evaluation of Furan/Pyrrole/Thiophene-2-carboxamide Derivatives as Efficient DNA GyraseB Inhibitors ofStaphylococcus aureus

  摘要：

  DNA topoisomerases are well‐validated targets in micro‐organisms. DNA gyraseB is one of the most important enzymes among them as per their clinical importance. In earlier study, a novel lead 4‐((4‐(furan‐2‐carboxamido)phenyl)amino)‐4‐oxobutanoic acid was identified as inhibitor against DNA gyraseB with an IC50 of 12.88 ± 1.39 μm. Subsequently, analogues of this lead were developed and evaluated through in vitro assays and in vivo studies. Among the 24 analogues, compound 22 was found to be the top hit with an improved DNA gyraseB activity of 5.35 ± 0.61 μm, and the binding affinity of this compound was further ascertained biophysically through differential scanning fluorimetry. The most potent ligand did not show any signs of cardiotoxicity in zebra fish ether‐ago‐go‐related gene, ascertaining the safety profile of this series a breakthrough among the previously reported cardiotoxic gyraseB inhibitors.

  DOI：

  10.1111/cbdd.12529
• 作为产物：
  描述：

  特定基氨基甲酸脂酶 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 7.0h， 生成 N-(4-氨基苯基)噻吩-2-甲酰胺
  参考文献：
  名称：

  Design and Biological Evaluation of Furan/Pyrrole/Thiophene-2-carboxamide Derivatives as Efficient DNA GyraseB Inhibitors ofStaphylococcus aureus

  摘要：

  DNA topoisomerases are well‐validated targets in micro‐organisms. DNA gyraseB is one of the most important enzymes among them as per their clinical importance. In earlier study, a novel lead 4‐((4‐(furan‐2‐carboxamido)phenyl)amino)‐4‐oxobutanoic acid was identified as inhibitor against DNA gyraseB with an IC50 of 12.88 ± 1.39 μm. Subsequently, analogues of this lead were developed and evaluated through in vitro assays and in vivo studies. Among the 24 analogues, compound 22 was found to be the top hit with an improved DNA gyraseB activity of 5.35 ± 0.61 μm, and the binding affinity of this compound was further ascertained biophysically through differential scanning fluorimetry. The most potent ligand did not show any signs of cardiotoxicity in zebra fish ether‐ago‐go‐related gene, ascertaining the safety profile of this series a breakthrough among the previously reported cardiotoxic gyraseB inhibitors.

  DOI：

  10.1111/cbdd.12529

文献信息

• Naphthalene Derivative
  申请人：Kakizuka Akira

  公开号：US20130184241A1

  公开（公告）日：2013-07-18

  The present invention provides compounds which can regulate VCP activity. The present invention provides the compound of formula (I) (R is as defined in the description) or oxides, esters, prodrugs, pharmaceutically acceptable salts or solvates thereof. The compounds can regulate VCP activity, and thus are useful for treating VCP-mediated diseases such as neurodegenerative diseases.

  本发明提供了可以调节VCP活性的化合物。本发明提供了式(I)的化合物（其中R如描述中所定义）或其氧化物、酯、前药、药学上可接受的盐或溶剂。这些化合物可以调节VCP活性，因此可用于治疗VCP介导的疾病，如神经退行性疾病。
• Targeting zoonotic viruses: Structure-based inhibition of the 3C-like protease from bat coronavirus HKU4—The likely reservoir host to the human coronavirus that causes Middle East Respiratory Syndrome (MERS)
  作者：Sarah E. St. John、Sakshi Tomar、Shaun R. Stauffer、Andrew D. Mesecar

  DOI：10.1016/j.bmc.2015.06.039

  日期：2015.9

  The bat coronavirus HKU4 belongs to the same 2c lineage as that of the deadly Middle East Respiratory Syndrome coronavirus (MERS-CoV) and shows high sequence similarity, therefore potentiating a threat to the human population through a zoonotic shift or 'spill over' event. To date, there are no effective vaccines or antiviral treatments available that are capable of limiting the pathogenesis of any human coronaviral infection. An attractive target for the development of anti-coronaviral therapeutics is the 3C-like protease (3CL(pro)), which is essential for the progression of the coronaviral life cycle. Herein, we report the screening results of a small, 230-member peptidomimetic library against HKU4-CoV 3CL(pro) and the identification of 43 peptidomimetic compounds showing good to excellent inhibitory potency of HKU4-CoV 3CL(pro) with IC50 values ranging from low micromolar to sub-micromolar. We established structure-activity relationships (SARs) describing the important ligand-based features required for potent HKU4-CoV 3CL(pro) inhibition and identified a seemingly favored peptidic backbone for HKU4-CoV 3CL(pro) inhibition. To investigate this, a molecular sub-structural analysis of the most potent HKU4-CoV 3CL(pro) inhibitor was accomplished by the synthesis and testing of the lead peptidomimetic inhibitor's sub-structural components, confirming the activity of the favored backbone (22A) identified via SAR analysis. In order to elucidate the structural reasons for such potent HKU4-CoV 3CL(pro) inhibition by the peptidomimetics having the 22A backbone, we determined the X-ray structures of HKU4-CoV 3CL(pro) in complex with three peptidomimetic inhibitors. Sequence alignment of HKU4-CoV 3CL(pro), and two other lineage C Betacoronaviruses 3CL(pro')s, HKU5-CoV and MERS-CoV 3CL(pro), show that the active site residues of HKU4-CoV 3CL(pro) that participate in inhibitor binding are conserved in HKU5-CoV and MERS-CoV 3CL(pro). Furthermore, we assayed our most potent HKU4-CoV 3CL(pro) inhibitor for inhibition of HKU5-CoV 3CL(pro) and found it to have sub-micromolar inhibitory activity (IC50 = 0.54 +/- 0.03 mu M). The X-ray structures and SAR analysis reveal critical insights into the structure and inhibition of HKU4-CoV 3CL(pro), providing fundamental knowledge that may be exploited in the development of anti-coronaviral therapeutics for coronaviruses emerging from zoonotic reservoirs. (C) 2015 Elsevier Ltd. All rights reserved.
• NAPHTHALENE DERIVATIVE
  申请人：Daito Chemix Corporation

  公开号：EP2599771B1

  公开（公告）日：2016-09-14
• US6380243B1
  申请人：——

  公开号：US6380243B1

  公开（公告）日：2002-04-30
• US9573887B2
  申请人：——

  公开号：US9573887B2

  公开（公告）日：2017-02-21